NASDAQ · ALNY
Healthcare · Biotechnology
$238.27
Down-$11.72 (-4.69%)
Updated Sep 16, 2026, 9:19 AM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ALNY closed at $238.27 after 20 trading sessions, up 4.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $246.99 | $247.425 | $237.44 | $238.27 | 2.18M |
| Sep 14, 2026 | $250.165 | $252.79 | $244.18 | $249.99 | 997.23K |
| Sep 11, 2026 | $248.05 | $254.08 | $246.01 | $248.68 | 1.18M |
| Sep 10, 2026 | $256.68 | $256.68 | $246.42 | $247.51 | 1.63M |
| Sep 9, 2026 | $257.07 | $261.98 | $253.275 | $258.00 | 1.43M |
| Sep 8, 2026 | $259.00 | $272.08 | $254.005 | $260.10 | 2.01M |
| Sep 4, 2026 | $258.58 | $266.85 | $258.02 | $266.11 | 1.43M |
| Sep 3, 2026 | $265.94 | $271.19 | $261.54 | $264.50 | 1.71M |
| Sep 2, 2026 | $246.48 | $269.94 | $246.48 | $267.40 | 3.29M |
| Sep 1, 2026 | $242.398 | $248.13 | $238.00 | $246.11 | 1.94M |
| Aug 31, 2026 | $235.94 | $243.02 | $233.3306 | $240.69 | 1.64M |
| Aug 28, 2026 | $224.465 | $239.08 | $223.61 | $237.10 | 1.85M |
| Aug 27, 2026 | $236.56 | $238.00 | $230.455 | $236.56 | 1.29M |
| Aug 26, 2026 | $238.54 | $242.89 | $236.60 | $239.00 | 1.12M |
| Aug 25, 2026 | $236.56 | $240.67 | $235.411 | $240.08 | 1.58M |
| Aug 24, 2026 | $235.83 | $237.905 | $228.59 | $236.01 | 2.14M |
| Aug 21, 2026 | $228.88 | $238.97 | $228.34 | $236.22 | 1.91M |
| Aug 20, 2026 | $239.00 | $240.88 | $228.74 | $229.30 | 1.7M |
| Aug 19, 2026 | $234.36 | $244.03 | $233.40 | $242.61 | 1.88M |
| Aug 18, 2026 | $226.27 | $230.91 | $222.01 | $228.61 | 1.6M |
The latest Smart Investors Daily articles mentioning ALNY.
ALNY research
Company profile and research snapshot.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | Jefferies | Hold | — |
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 14, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 4, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 11, 2026
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 15.67%. Currently, Alnylam Pharmaceuticals has a market
Yahoo · Sep 10, 2026
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]
SeekingAlpha · Sep 8, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 8:45 AM EDTCompany ParticipantsJohn Kennedy - Senior...
Yahoo · Sep 4, 2026
170-Page Report Tracks Intellia and Regeneron's Nex-Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR TreatmentDublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- "Hereditary Transthyretin Amyloidosis - Market Insight, Epidemiology, and Market Forecast - 2036" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of hATTR, its historical and forecasted epidemiology, and market trends
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALNY.
